We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-3.09%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.9B
AUM Growth
-$244M
Cap. Flow
-$155M
Cap. Flow %
-8.17%
Top 10 Hldgs %
53.17%
Holding
39
New
8
Increased
10
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$81.5M
2
ALKS icon
Alkermes
ALKS
+$72.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$50.7M
4
NVO
Novo Nordisk
NVO
+$35.4M
5
ABBV icon
AbbVie
ABBV
+$34.3M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$67.6M
2
MDCO
Medicines Co
MDCO
+$62M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$60M
4
AGN
Allergan plc
AGN
+$40.7M
5
DVA icon
DaVita
DVA
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$168M 8.85%
1,000,000
-250,000
-20% -$40.7M
VTRS icon
2
Viatris
VTRS
$20.7B
$168M 8.84%
8,500,000
-750,000
-8% -$14.7M
PRGO icon
3
Perrigo
PRGO
$1.43B
$95M 5%
1,700,000
-300,000
-15% -$15.3M
BKD icon
4
Brookdale Senior Living
BKD
$3.49B
$94.8M 4.98%
12,500,000
– –
DVA icon
5
DaVita
DVA
$15.3B
$85.6M 4.5%
1,500,000
-500,000
-25% -$29M
AGN
6
CALL
DELISTED
Allergan plc
AGN
$84.1M 4.42%
500,000
– –
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$83.2M 4.38%
850,000
+450,000
+113% +$50.7M
BIIB icon
8
Biogen
BIIB
$30.7B
$81.5M 4.29%
+350,000
New +$81.5M
BMY icon
9
Bristol-Myers Squibb
BMY
$132B
$76.1M 4%
1,500,000
+500,000
+50% +$23.5M
UHS icon
10
Universal Health Services
UHS
$9.88B
$74.4M 3.91%
500,000
-150,000
-23% -$21.5M
HCA icon
11
HCA Healthcare
HCA
$85.7B
$72.3M 3.8%
600,000
– –
THC icon
12
Tenet Healthcare
THC
$21.8B
$69.7M 3.66%
3,150,000
+650,000
+26% +$13.8M
ALKS icon
13
Alkermes
ALKS
$8.39B
$68.3M 3.59%
3,500,000
+3,311,719
+1,759% +$72.1M
ASND icon
14
Ascendis Pharma A/S
ASND
$16.5B
$62.6M 3.29%
650,000
– –
VTRS icon
15
CALL
Viatris
VTRS
$20.7B
$59.3M 3.12%
3,000,000
– –
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.64B
$56.5M 2.97%
750,000
+250,000
+50% +$29.5M
NKTR icon
17
Nektar Therapeutics
NKTR
$2.41B
$54.6M 2.87%
200,000
+33,333
+20% +$12.2M
AMAG
18
DELISTED
AMAG Pharmaceuticals
AMAG
$50.7M 2.67%
4,390,000
+1,390,000
+46% +$14.6M
MNTA
19
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$45.4M 2.39%
3,500,000
– –
ATRA icon
20
Atara Biotherapeutics
ATRA
$73.6M
$41.7M 2.19%
118,000
+38,000
+48% +$14.2M
ABBV icon
21
AbbVie
ABBV
$455B
$37.9M 1.99%
+500,000
New +$34.3M
ZYME icon
22
Zymeworks
ZYME
$1.67B
$37.2M 1.96%
1,500,000
-1,100,000
-42% -$27.6M
NVO
23
Novo Nordisk
NVO
$228B
$36.2M 1.9%
+1,400,000
New +$35.4M
UTHR icon
24
United Therapeutics
UTHR
$26.2B
$31.9M 1.68%
400,000
+32,471
+9% +$2.61M
THOR
25
DELISTED
Synthorx, Inc. Common Stock
THOR
$30.3M 1.59%
1,862,116
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Camber Capital Management held 39 positions worth $1.9B, down 11% from $2.15B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Camber Capital Management withdrew a net $155M in Q3 2019, closing 5 positions and reducing 6 holdings. Its most notable exit was Gilead Sciences, an estimated $67.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 75% a quarter earlier.

Against the trend, Camber Capital Management opened a new position in Biogen worth $81.5M.

  • Camber Capital Management's largest Q3 2019 buy was Biogen: 350,000 shares worth $81.5M.
  • Camber Capital Management added most to Alkermes in Q3 2019, an estimated $72.1M increase.
  • Camber Capital Management's biggest Q3 2019 reduction was Allergan plc, cutting an estimated $40.7M.
  • Camber Capital Management fully exited Gilead Sciences in Q3 2019, selling an estimated $67.6M.
  • Camber Capital Management's ten largest holdings make up 53% of its $1.9B portfolio in Q3 2019.
  • Camber Capital Management opened 8 new positions and closed 5 in Q3 2019.
  • Camber Capital Management's portfolio value fell 11% quarter-over-quarter to $1.9B.

Based on Camber Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.